JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Начало・Списък с акции・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Затворен

СекторЗдравеопазване

38.43 3.39

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

36.45

Максимум

38.59

Ключови измерители
By Trading Economics
Приходи	-19M -213M
EPS	-1.13
Марж на печалбата	-74.379
Служители	616
EBITDA	-24M -237M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+83.48% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-644M 6.9B
Предишно отваряне	35.04
Предишно затваряне	38.43

Настроения в новините

By Acuity

50%

175 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

40.67 / 41.96 Подкрепа & съпротива

REVOLUTION Medicines Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2025 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4.08.2025 г., 21:21 ч. UTC

Печалби

Значими двигатели на пазара

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4.08.2025 г., 20:45 ч. UTC

Печалби

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4.08.2025 г., 19:15 ч. UTC

Значими двигатели на пазара

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4.08.2025 г., 23:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.08.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Rise on Fed Stimulus Hopes

4.08.2025 г., 23:28 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.08.2025 г., 23:28 ч. UTC

Пазарно говорене

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4.08.2025 г., 21:30 ч. UTC

Печалби

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4.08.2025 г., 21:21 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4.08.2025 г., 21:18 ч. UTC

Печалби

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4.08.2025 г., 20:25 ч. UTC

Пазарно говорене

India Hits Back Over Russian Oil Purchases -- Market Talk

4.08.2025 г., 20:25 ч. UTC

Печалби

Transocean 2Q Loss $938M >RIG

4.08.2025 г., 20:25 ч. UTC

Печалби

Transocean 2Q Loss/Shr $1.06 >RIG

4.08.2025 г., 20:18 ч. UTC

Печалби

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4.08.2025 г., 20:15 ч. UTC

Печалби

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4.08.2025 г., 20:14 ч. UTC

Печалби

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4.08.2025 г., 20:14 ч. UTC

Печалби

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4.08.2025 г., 20:14 ч. UTC

Печалби

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4.08.2025 г., 20:13 ч. UTC

Печалби

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4.08.2025 г., 20:09 ч. UTC

Печалби

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4.08.2025 г., 20:06 ч. UTC

Печалби

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4.08.2025 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4.08.2025 г., 19:41 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower -- Market Talk

4.08.2025 г., 19:28 ч. UTC

Пазарно говорене

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4.08.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4.08.2025 г., 18:27 ч. UTC

Пазарно говорене

Gold Climbs on Rate Cut Speculation -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

REVOLUTION Medicines Inc Прогноза

Ценова цел

By TipRanks

83.48% нагоре

12-месечна прогноза

Среден 67.21 USD 83.48%

Висок 80 USD

Нисък 37.91 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за REVOLUTION Medicines Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на REVOLUTION Medicines Inc през последните 3 месеца.

Техническа оценка

By Trading Central

40.67 / 41.96Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Настроение

By Acuity

175 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.